Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bi-2536. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 known ✓ | P53350 | 12/20 | 1.00 |
| ▸ | BRD4 | O60885 | 15/20 | 1.00 |
| ▸ | PLK3 | Q9H4B4 | 6/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 5/20 | 1.00 |
| ▸ | TAF1 | P21675 | 5/20 | 1.00 |
| ▸ | PLK2 | Q9NYY3 | 4/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 3/20 | 1.00 |
| ▸ | CLK2 | P49760 | 3/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 3/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 3/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 3/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 1.00 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 1.00 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 2/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bi-2536 SCHEMBL29395966 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL614114 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL16984416 | 1.00 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| Bi-2536 SCHEMBL29644993 | 0.99 | BRD4 (0.99) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL13227794 | 0.96 | BRD4 (0.92) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL24851804 | 0.96 | PLK1 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL4515444 | 0.95 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972068 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL16972069 | 0.94 | BRD4 (1.00) | BRD4PLK1PLK3ALKTAF1 | |
| SCHEMBL376236 | 0.94 | PLK1 (0.89) | BRD4PLK1PLK3ALKTAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1058 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2026-05-19 | — | — | US | claimed |
| CN-122005814-A | Drug-loaded polymer micelle, gel drug system, preparation method and application | 苏州大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-04-02 | — | — | US | claimed |
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | claimed |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | CELGENE CORPORATION (US) | 2025-08-26 | — | — | US | claimed |
| EP-4583983-A1 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | Cardiff Oncology, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4583982-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | Cardiff Oncology, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2022087371-A1 | NOVEL BICYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022087375-A1 | NOVEL HETEROCYCLIC COMPOUNDS | SPECTRUM PHARMACEUTICALS, INC. (US) | 2022-04-28 | — | — | WO | claimed |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-04-28 | — | — | US | claimed |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | FELICITEX THERAPEUTICS, INC. | 2022-04-14 | — | — | US | claimed |
| EP-3976195-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| WO-2022055721-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-17 | — | — | WO | claimed |
| CN-114096280-A | Therapeutic constructs for co-delivery of mitotic kinase inhibitors and immune checkpoint inhibitors | 俄勒冈健康与科学大学 | 2022-02-25 | — | — | CN | claimed |
| EP-3946313-A1 | PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER | Cardiff Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-20180369214-A1 | Methods of Diagnosing and Treating Small Cell Lung Cancer Using Polo-Like Kinase 1 (PLK1) Inhibitors | EMORY UNIVERSITY | 2018-12-27 | — | — | US | claimed |
| US-20080300206-A1 | Alpha-Synuclein Kinase | ELAN PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076970-A1 | CANCER TREATMENT USING MTDP INHIBITORS AND PLK1 INHIBITORS | PLK1, PLK4, PLK2 | PLK1 1/4885BRD4 660/4885PLK3 7/4885 |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-12396995-B2 | Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use | DOT1L, CARM1, EZH2 | PLK1 19/4885BRD4 13/4885PLK3 501/4885 |
| US-20080300206-A1 | Alpha-Synuclein Kinase | SNCA, PLK2, LMTK2 | PLK1 24/4885BRD4 1493/4885PLK3 6/4885 |
| US-20220127682-A1 | SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIES | PLK4, PLK2, BUB1B | PLK1 5/4885BRD4 1076/4885PLK3 4/4885 |
| US-20220110941-A1 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS | BUB1B, BUB1, CCNB1 | PLK1 5/4885BRD4 316/4885PLK3 370/4885 |
| US-20260092327-A1 | METHODS OF MONITORING MUTATIONS IN TREATMENT OF COLORECTAL CANCER | KRAS, HRAS, NRAS | PLK1 25/4885BRD4 1886/4885PLK3 103/4885 |
| US-12630532-B2 | Indole-substituted quinolines and their combination with Plk1 inhibitors for the treatment of cancer | PLK1, MYC, PLK4 | PLK1 1/4885BRD4 118/4885PLK3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.